TSE:4076 stock news
This page provides real-time market news, earnings updates, and company announcements related to CNS Co.,Ltd. (TSE:4076).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-25 09:29 JST
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-16 22:06:42
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
Finviz2026-03-17 11:33:50
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026
Finviz2026-03-17 12:03:54
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-17 20:36:49
Nuvation Bio Presents 50-Month DOR at AACR 2026: Does IBTROZI’s Long-Term Efficacy Signal a Valuation Upside or Potential Mispricing?
101 finance2026-03-17 21:01:07
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-18 10:12:46
Ovid’s $60M PIPE Removes Cash Crunch Overhang Before Q2 2026 OV329 Trial Catalyst
101 finance2026-03-18 11:00:52
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Finviz2026-03-18 12:18:42
This recent $7 million investment focuses on a CNS pharmaceutical company currently conducting a Phase 3 trial, with its stock rising by 27%.
101 finance2026-03-18 16:00:51
This recent $7 million investment focuses on a CNS pharmaceutical company currently conducting a Phase 3 trial, with its stock rising by 27%.
101 finance2026-03-18 17:30:24
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Finviz2026-03-18 21:03:57
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP
Finviz2026-03-19 13:04:04
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Finviz2026-03-19 14:03:58
Curis Provides Fourth Quarter 2025 Business Update
Finviz2026-03-19 20:04:01
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript
101 finance2026-03-19 21:48:40
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript
101 finance2026-03-19 21:54:40
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call
101 finance2026-03-19 23:06:47
Collegium’s rapid-growth ADHD platform drives the widening of its competitive advantage—however, underwhelming earnings suggest potential threats to profit margins
101 finance2026-03-22 19:39:57
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Finviz2026-03-23 13:01:26
MIRA Explodes 23% on Groundbreaking Pain Research; Can This Surge Sustain?
101 finance2026-03-23 17:12:45
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Finviz2026-03-23 20:09:47
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Finviz2026-03-23 20:36:10
Theravance Ends 12-Year Loss Streak With Record Q4 Profit
101 finance2026-03-24 03:39:56
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
Finviz2026-03-24 13:07:06
Nuvation Bio Presents 50-Month DOR at AACR 2026: Does IBTROZI’s Long-Term Efficacy Signal a Valuation Upside or Potential Mispricing?
101 finance2026-03-17 21:01:07
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-18 10:12:46
Ovid’s $60M PIPE Removes Cash Crunch Overhang Before Q2 2026 OV329 Trial Catalyst
101 finance2026-03-18 11:00:52
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Finviz2026-03-18 12:18:42
This recent $7 million investment focuses on a CNS pharmaceutical company currently conducting a Phase 3 trial, with its stock rising by 27%.
101 finance2026-03-18 16:00:51
This recent $7 million investment focuses on a CNS pharmaceutical company currently conducting a Phase 3 trial, with its stock rising by 27%.
101 finance2026-03-18 17:30:24
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Finviz2026-03-18 21:03:57
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP
Finviz2026-03-19 13:04:04
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Finviz2026-03-19 14:03:58
Curis Provides Fourth Quarter 2025 Business Update
Finviz2026-03-19 20:04:01
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript
101 finance2026-03-19 21:48:40
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript
101 finance2026-03-19 21:54:40
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call
101 finance2026-03-19 23:06:47
Collegium’s rapid-growth ADHD platform drives the widening of its competitive advantage—however, underwhelming earnings suggest potential threats to profit margins
101 finance2026-03-22 19:39:57
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Finviz2026-03-23 13:01:26
MIRA Explodes 23% on Groundbreaking Pain Research; Can This Surge Sustain?
101 finance2026-03-23 17:12:45
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Finviz2026-03-23 20:09:47
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Finviz2026-03-23 20:36:10
Theravance Ends 12-Year Loss Streak With Record Q4 Profit
101 finance2026-03-24 03:39:56
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
Finviz2026-03-24 13:07:06
TSE:4076 stock price change
On the last trading day, TSE:4076 stock closed at 1632.00 JPY, with a price change of -3.94% for the day.
Trade stock perpsTSE:4076 stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more